Ginkgo Bioworks Holdings Key Executives
This section highlights Ginkgo Bioworks Holdings's key executives, including their titles and compensation details.
Find Contacts at Ginkgo Bioworks Holdings
( total contacts)
Ginkgo Bioworks Holdings Earnings
This section highlights Ginkgo Bioworks Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-25 | $-1.45 | $-1.82 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-2.40 | $-1.08 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $-3.20 | $-3.20 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-3.20 | $-3.20 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | $-3.60 | $-3.60 |
| Read Transcript | Q3 | 2023 | 2023-11-10 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-10 | $-3.60 | $-3.20 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
$7.48
Stock Price
$434.09M
Market Cap
834
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Ginkgo Bioworks Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $227.04M | $251.46M | $477.71M | $313.84M | $76.66M |
| Cost of Revenue | $38.55M | $54.01M | $204.22M | $129.69M | $15.61M |
| Gross Profit | $188.49M | $197.45M | $273.49M | $184.15M | $61.05M |
| Gross Profit Ratio | 83.02% | 78.50% | 57.25% | 58.70% | 79.64% |
| Research and Development Expenses | $424.06M | $580.62M | $1.05B | $1.15B | $159.77M |
| General and Administrative Expenses | $246.16M | $385.02M | $1.43B | $862.95M | $38.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $246.16M | $385.02M | $1.43B | $862.95M | $38.31M |
| Other Expenses | $78.03M | $96.21M | $7.63M | $-1.73M | $16.12M |
| Operating Expenses | $748.25M | $1.06B | $2.48B | $2.01B | $198.07M |
| Cost and Expenses | $786.80M | $1.12B | $2.69B | $2.14B | $213.68M |
| Interest Income | $38.61M | $57.22M | $20.26M | $837.00K | $2.58M |
| Interest Expense | $94.00K | $93.00K | $106.00K | $2.37M | $2.38M |
| Depreciation and Amortization | $63.02M | $71.55M | $61.63M | $29.08M | $13.86M |
| EBITDA | $-484.39M | $-821.29M | $-2.06B | $-1.81B | $-108.58M |
| EBITDA Ratio | -213.35% | -326.62% | -456.43% | -598.26% | -140.25% |
| Operating Income | $-559.76M | $-864.41M | $-2.21B | $-1.83B | $-137.03M |
| Operating Income Ratio | -246.54% | -343.76% | -462.41% | -582.62% | -178.75% |
| Total Other Income Expenses Net | $12.25M | $-28.53M | $87.55M | $-9.65M | $12.19M |
| Income Before Tax | $-547.51M | $-892.94M | $-2.12B | $-1.84B | $-124.83M |
| Income Before Tax Ratio | -241.15% | -355.11% | -444.08% | -585.69% | -162.85% |
| Income Tax Expense | $-479.00K | $-71.00K | $-15.03M | $-1.48M | $1.89M |
| Net Income | $-547.03M | $-892.87M | $-2.10B | $-1.83B | $-126.61M |
| Net Income Ratio | -240.94% | -355.08% | -440.63% | -583.12% | -165.16% |
| EPS | $-10.54 | $-18.37 | $-50.15 | $-53.83 | $-3.97 |
| EPS Diluted | $-10.54 | $-18.40 | $-50.20 | $-55.53 | $-4.00 |
| Weighted Average Shares Outstanding | 51.89M | 48.53M | 41.93M | 32.95M | 31.65M |
| Weighted Average Shares Outstanding Diluted | 51.89M | 48.61M | 42.00M | 34.01M | 31.87M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.85M | $89.05M | $56.21M | $37.94M | $34.76M | $55.43M | $80.57M | $80.70M | $98.28M | $66.40M | $144.62M | $168.41M | $148.49M | $77.61M | $43.64M | $44.10M | $32.06M | $13.30M | $10.16M | $21.13M |
| Cost of Revenue | $9.62M | $9.99M | $31.05M | $22.07M | $15.95M | $6.92M | $18.10M | $22.38M | $30.22M | $24.66M | $63.91M | $85.43M | $66.58M | $22.30M | $17.11M | $23.70M | $13.84M | $1.77M | $- | $- |
| Gross Profit | $34.23M | $79.06M | $25.16M | $15.87M | $18.81M | $48.51M | $62.47M | $58.33M | $68.07M | $41.74M | $80.71M | $82.97M | $81.92M | $55.31M | $26.53M | $20.40M | $18.22M | $11.53M | $10.16M | $21.13M |
| Gross Profit Ratio | 78.10% | 88.80% | 44.80% | 41.80% | 54.10% | 87.50% | 77.50% | 72.30% | 69.30% | 62.90% | 55.80% | 49.30% | 55.20% | 71.30% | 60.80% | 46.30% | 56.82% | 86.70% | 100.00% | 100.00% |
| Research and Development Expenses | $76.38M | $77.01M | $134.22M | $123.59M | $107.70M | $156.66M | $144.28M | $162.64M | $181.16M | $259.58M | $289.19M | $322.72M | $985.02M | $53.02M | $52.03M | $59.59M | $61.19M | $36.07M | $32.27M | $30.24M |
| General and Administrative Expenses | $57.30M | $52.29M | $66.28M | $70.29M | $89.22M | $82.03M | $102.34M | $111.43M | $121.42M | $435.18M | $438.43M | $434.77M | $781.63M | $28.96M | $34.44M | $17.93M | $12.91M | $9.88M | $8.95M | $6.57M |
| Selling and Marketing Expenses | $- | $- | $- | $-19.27M | $-23.66M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $57.30M | $52.29M | $66.28M | $51.02M | $65.56M | $82.03M | $102.34M | $111.43M | $121.42M | $435.18M | $438.43M | $434.77M | $781.63M | $28.96M | $34.44M | $17.93M | $12.91M | $9.88M | $8.95M | $6.57M |
| Other Expenses | $4.16M | $4.96M | $64.92M | $2.02M | $93.00K | $2.89M | $3.22M | $2.93M | $7.00M | $-957.00K | $-51.00K | $1.64M | $-1.62M | $-4.91M | $7.12M | $-1.34M | $1.78M | $5.89M | $- | $- |
| Operating Expenses | $137.83M | $134.26M | $267.34M | $174.61M | $173.26M | $238.69M | $246.62M | $274.07M | $302.57M | $694.76M | $727.62M | $757.49M | $1.77B | $81.98M | $86.47M | $77.51M | $74.10M | $45.95M | $38.72M | $45.95M |
| Cost and Expenses | $147.45M | $144.25M | $279.15M | $196.68M | $189.21M | $245.61M | $264.72M | $296.45M | $332.79M | $719.42M | $791.53M | $842.92M | $1.83B | $104.28M | $103.58M | $101.21M | $87.95M | $47.72M | $38.72M | $45.95M |
| Interest Income | $7.34M | $9.25M | $10.31M | $11.71M | $13.30M | $15.02M | $14.35M | $14.54M | $13.06M | $5.82M | $2.26M | $177.00K | $496.00K | $121.00K | $- | $- | $- | $3.32M | $169.00K | $1.21M |
| Interest Expense | $94.00K | $- | $- | $- | $93.00K | $- | $- | $- | $13.06M | $1.67M | $37.13M | $397.00K | $551.00K | $649.00K | $- | $475.00K | $- | $592.00K | $- | $- |
| Depreciation and Amortization | $15.65M | $17.17M | $17.33M | $12.87M | $12.84M | $29.37M | $25.94M | $27.00M | $33.03M | $9.51M | $9.61M | $9.49M | $8.00M | $8.28M | $7.17M | $5.63M | $4.00M | $3.53M | $3.18M | $3.15M |
| EBITDA | $-143.48M | $-35.93M | $-136.94M | $-165.13M | $-269.13M | $-151.16M | $-166.50M | $-196.79M | $-155.89M | $-646.02M | $-638.75M | $-666.43M | $-1.60B | $-17.79M | $-52.78M | $-51.49M | $-51.88M | $-22.00M | $-27.88M | $-12.52M |
| EBITDA Ratio | -327.24% | -40.35% | -243.65% | -384.43% | -407.47% | -70.45% | -197.75% | -237.44% | -238.29% | -986.18% | -430.19% | -406.33% | -1138.44% | -80.96% | -127.27% | -184.72% | -160.11% | -191.23% | -274.30% | -59.22% |
| Operating Income | $-103.61M | $-55.20M | $-222.94M | $-158.74M | $-154.45M | $-286.39M | $-184.15M | $-215.75M | $-234.51M | $-653.02M | $-646.91M | $-674.51M | $-1.68B | $-26.67M | $-59.95M | $-57.12M | $-55.89M | $-34.41M | $-31.06M | $-15.67M |
| Operating Income Ratio | -236.29% | -61.99% | -396.66% | -418.35% | -444.41% | -516.68% | -228.57% | -267.34% | -238.60% | -983.49% | -447.32% | -400.53% | -1134.55% | -34.37% | -137.38% | -129.52% | -174.33% | -258.71% | -305.58% | -74.15% |
| Total Other Income Expenses Net | $-4.25M | $-1.57M | $5.95M | $12.12M | $-33.77M | $-16.52M | $10.90M | $10.86M | $45.58M | $-16.06M | $-23.71M | $81.74M | $79.06M | $-75.94M | $5.05M | $-17.82M | $9.50M | $8.29M | $2.33M | $-7.93M |
| Income Before Tax | $-107.86M | $-56.78M | $-216.99M | $-165.88M | $-211.89M | $-302.91M | $-173.25M | $-204.89M | $-188.92M | $-669.08M | $-670.62M | $-592.78M | $-1.61B | $-102.61M | $-54.90M | $-74.94M | $-46.39M | $-26.12M | $-28.72M | $-23.60M |
| Income Before Tax Ratio | -245.99% | -63.76% | -386.06% | -437.17% | -609.67% | -546.48% | -215.03% | -253.88% | -192.22% | -1007.69% | -463.71% | -351.99% | -1081.31% | -132.21% | -125.80% | -169.94% | -144.71% | -196.36% | -282.63% | -111.66% |
| Income Tax Expense | $-325.00K | $-375.00K | $190.00K | $31.00K | $-198.00K | $-22.00K | $67.00K | $82.00K | $-14.77M | $-28.00K | $-45.00K | $-184.00K | $-683.00K | $-207.00K | $-431.00K | $-159.00K | $8.00K | $6.00K | $6.00K | $1.87M |
| Net Income | $-107.53M | $-56.40M | $-217.18M | $-165.91M | $-211.69M | $-302.89M | $-173.31M | $-204.97M | $-176.54M | $-670.13M | $-668.83M | $-590.50M | $-1.60B | $-101.88M | $-53.94M | $-73.57M | $-46.92M | $-26.05M | $-28.66M | $-24.97M |
| Net Income Ratio | -245.25% | -63.34% | -386.40% | -437.25% | -609.10% | -546.44% | -215.12% | -253.98% | -179.62% | -1009.26% | -462.48% | -350.65% | -1077.93% | -131.27% | -123.62% | -166.83% | -146.37% | -195.87% | -281.98% | -118.16% |
| EPS | $-2.07 | $-1.08 | $-4.23 | $-3.31 | $-4.28 | $-6.21 | $-3.59 | $-4.28 | $-3.78 | $-16.44 | $-16.51 | $-14.69 | $-41.82 | $-3.08 | $-1.67 | $-2.28 | $-1.46 | $-0.81 | $-0.94 | $-0.82 |
| EPS Diluted | $-2.07 | $-1.08 | $-4.23 | $-3.32 | $-4.31 | $-6.21 | $-3.60 | $-4.29 | $-3.85 | $-16.44 | $-16.51 | $-14.80 | $-43.34 | $-3.08 | $-1.67 | $-2.28 | $-1.48 | $-0.81 | $-0.94 | $-0.82 |
| Weighted Average Shares Outstanding | 51.89M | 52.24M | 51.33M | 49.99M | 49.11M | 48.77M | 48.14M | 47.77M | 45.60M | 40.77M | 40.52M | 39.90M | 36.94M | 33.09M | 32.31M | 32.26M | 31.62M | 32.18M | 30.45M | 30.45M |
| Weighted Average Shares Outstanding Diluted | 51.89M | 52.25M | 51.38M | 50.13M | 49.47M | 48.77M | 48.34M | 47.92M | 46.42M | 40.77M | 40.52M | 40.19M | 38.29M | 33.09M | 32.31M | 32.26M | 32.20M | 32.18M | 30.45M | 30.45M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $561.57M | $944.07M | $1.32B | $1.55B | $380.80M |
| Short Term Investments | $- | $-654.00K | $- | $- | $- |
| Cash and Short Term Investments | $561.57M | $944.07M | $1.32B | $1.55B | $380.80M |
| Net Receivables | $21.86M | $31.74M | $82.47M | $149.90M | $21.91M |
| Inventory | $- | $46.00K | $4.36M | $3.36M | $2.74M |
| Other Current Assets | $19.32M | $25.89M | $47.46M | $19.78M | $21.10M |
| Total Current Assets | $602.74M | $1.00B | $1.45B | $1.72B | $426.54M |
| Property Plant Equipment Net | $598.15M | $397.22M | $715.53M | $145.77M | $121.44M |
| Goodwill | $- | $49.24M | $60.21M | $21.31M | $1.86M |
| Intangible Assets | $72.51M | $82.74M | $111.04M | $21.64M | $3.29M |
| Goodwill and Intangible Assets | $72.51M | $131.98M | $171.25M | $42.95M | $5.15M |
| Long Term Investments | $48.70M | $78.56M | $113.73M | $115.23M | $103.12M |
| Tax Assets | $- | $- | $- | $- | $13.30M |
| Other Non-Current Assets | $55.34M | $55.83M | $88.72M | $43.99M | $5.60M |
| Total Non-Current Assets | $774.71M | $663.59M | $1.09B | $347.94M | $248.61M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.38B | $1.67B | $2.54B | $2.07B | $675.15M |
| Account Payables | $14.17M | $9.32M | $10.45M | $8.19M | $13.89M |
| Short Term Debt | $- | $19.93M | $29.33M | $747.00K | $485.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $27.71M | $48.49M | $47.82M | $33.24M | $28.82M |
| Other Current Liabilities | $65.39M | $86.11M | $85.36M | $92.58M | $30.02M |
| Total Current Liabilities | $107.27M | $163.86M | $172.96M | $134.76M | $73.22M |
| Long Term Debt | $438.77M | $221.84M | $413.26M | $22.28M | $-108.49M |
| Deferred Revenue Non-Current | $- | $158.06M | $174.77M | $155.99M | $99.65M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $154.58M | $12.68M |
| Other Non-Current Liabilities | $115.36M | $24.43M | $42.06M | $190.58M | $-9.65M |
| Total Non-Current Liabilities | $554.12M | $404.33M | $630.08M | $368.85M | $131.88M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $661.39M | $568.19M | $803.04M | $503.61M | $205.10M |
| Preferred Stock | $- | $- | $- | $- | $0 |
| Common Stock | $5.00K | $199.00K | $190.00K | $161.00K | $129.00K |
| Retained Earnings | $-5.84B | $-5.29B | $-4.40B | $-2.30B | $-467.88M |
| Accumulated Other Comprehensive Income Loss | $-1.81M | $1.48M | $-2.63M | $-1.72M | $-0 |
| Other Total Stockholders Equity | $6.56B | $6.39B | $6.14B | $3.80B | $929.12M |
| Total Stockholders Equity | $716.06M | $1.10B | $1.74B | $1.51B | $461.38M |
| Total Equity | $716.06M | $1.10B | $1.74B | $1.57B | $470.05M |
| Total Liabilities and Stockholders Equity | $1.38B | $1.67B | $2.54B | $2.07B | $675.15M |
| Minority Interest | $- | $- | $- | $62.01M | $8.68M |
| Total Liabilities and Total Equity | $1.38B | $1.67B | $2.54B | $2.07B | $675.15M |
| Total Investments | $48.70M | $77.91M | $113.73M | $115.23M | $103.12M |
| Total Debt | $438.77M | $241.77M | $442.59M | $23.03M | $17.00M |
| Net Debt | $-122.81M | $-702.30M | $-873.20M | $-1.53B | $-363.80M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 | December 31, 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $561.57M | $616.21M | $730.37M | $843.77M | $948.86M | $1.05B | $1.11B | $1.21B | $1.32B | $1.30B | $1.38B | $1.49B | $1.55B | $1.74B | $37.63K | $1.92M | $380.80M | $-495.29M | $1.55B |
| Short Term Investments | $- | $- | $57.80M | $- | $- | $-643.00K | $-25.00K | $- | $- | $-4.46M | $- | $- | $- | $- | $1.73B | $1.73B | $- | $990.57M | $- |
| Cash and Short Term Investments | $561.57M | $616.21M | $730.37M | $843.77M | $948.86M | $1.05B | $1.11B | $1.21B | $1.32B | $1.30B | $1.38B | $1.49B | $1.55B | $1.74B | $37.63K | $1.92M | $380.80M | $495.29M | $1.55B |
| Net Receivables | $21.86M | $23.41M | $18.89M | $24.56M | $31.74M | $63.14M | $68.92M | $84.84M | $82.47M | $115.76M | $174.88M | $171.07M | $149.90M | $50.73M | $- | $- | $21.91M | $- | $131.54M |
| Inventory | $- | $- | $- | $1 | $46.00K | $70.00K | $391.00K | $2.51M | $4.36M | $5.86M | $8.10M | $8.70M | $3.36M | $3.47M | $2.72M | $3.42M | $2.74M | $- | $3.36M |
| Other Current Assets | $19.32M | $22.86M | $34.10M | $38.02M | $25.89M | $29.39M | $48.36M | $33.87M | $47.46M | $37.78M | $38.72M | $33.09M | $19.78M | $17.31M | $929.25K | $1.07M | $21.10M | $- | $38.13M |
| Total Current Assets | $602.74M | $662.48M | $783.36M | $903.02M | $1.00B | $1.14B | $1.22B | $1.33B | $1.45B | $1.46B | $1.60B | $1.71B | $1.72B | $1.81B | $966.88K | $2.99M | $426.54M | $495.29M | $1.72B |
| Property Plant Equipment Net | $598.15M | $616.95M | $628.59M | $416.78M | $397.22M | $543.21M | $685.67M | $702.24M | $715.53M | $187.58M | $176.22M | $149.17M | $145.77M | $142.70M | $145.88M | $141.92M | $121.44M | $- | $145.77M |
| Goodwill | $- | $- | $- | $47.91M | $49.24M | $58.06M | $58.83M | $58.73M | $60.21M | $28.80M | $30.97M | $21.04M | $21.31M | $16.66M | $1.86M | $1.86M | $1.86M | $- | $21.31M |
| Intangible Assets | $72.51M | $79.57M | $90.60M | $77.41M | $82.74M | $100.17M | $105.03M | $108.74M | $111.04M | $47.94M | $39.18M | $20.83M | $21.64M | $22.57M | $3.02M | $3.16M | $3.29M | $- | $21.64M |
| Goodwill and Intangible Assets | $72.51M | $79.57M | $90.60M | $125.32M | $131.98M | $158.22M | $163.86M | $167.46M | $171.25M | $76.74M | $70.15M | $41.87M | $42.95M | $39.23M | $4.88M | $5.01M | $5.15M | $- | $42.95M |
| Long Term Investments | $48.70M | $62.10M | $62.49M | $133.94M | $132.89M | $85.61M | $119.97M | $122.94M | $113.73M | $100.44M | $95.98M | $111.24M | $115.23M | $121.13M | $1.73B | $1.73B | $103.12M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $477.00K | $1.09M | $- | $- | $- | $- | $- | $- | $10.16M | $-192.85M | $-169.59M | $13.30M | $- | $- |
| Other Non-Current Assets | $55.34M | $59.79M | $60.21M | $2.71M | $1.50M | $97.02M | $97.95M | $97.26M | $88.72M | $43.93M | $53.02M | $49.62M | $43.99M | $26.80M | $-150.76M | $-146.93M | $5.60M | $-495.29M | $159.22M |
| Total Non-Current Assets | $774.71M | $818.40M | $841.89M | $678.74M | $663.59M | $884.55M | $1.07B | $1.09B | $1.09B | $408.69M | $395.37M | $351.89M | $347.94M | $340.02M | $1.73B | $1.73B | $248.61M | $-495.29M | $347.94M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- |
| Total Assets | $1.38B | $1.48B | $1.63B | $1.58B | $1.67B | $2.03B | $2.29B | $2.42B | $2.54B | $1.87B | $1.99B | $2.06B | $2.07B | $2.15B | $1.73B | $1.73B | $675.15M | $- | $2.07B |
| Account Payables | $14.17M | $15.70M | $23.03M | $27.00M | $9.32M | $10.75M | $13.63M | $21.57M | $10.45M | $11.32M | $19.46M | $35.26M | $8.19M | $7.10M | $2.77M | $14.23M | $13.89M | $- | $8.19M |
| Short Term Debt | $- | $- | $- | $- | $19.93M | $- | $- | $- | $29.33M | $- | $- | $- | $747.00K | $- | $- | $- | $485.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $27.71M | $22.89M | $26.01M | $33.61M | $48.49M | $42.76M | $39.22M | $47.52M | $47.82M | $40.51M | $45.50M | $35.23M | $33.24M | $29.65M | $- | $- | $28.82M | $- | $33.24M |
| Other Current Liabilities | $65.39M | $75.83M | $117.12M | $108.44M | $86.11M | $114.95M | $110.48M | $122.61M | $85.36M | $72.99M | $70.06M | $88.76M | $92.58M | $53.55M | $1.92M | $-12.81M | $58.84M | $- | $93.33M |
| Total Current Liabilities | $107.27M | $114.43M | $166.15M | $169.04M | $163.86M | $168.46M | $163.33M | $191.70M | $172.96M | $124.82M | $135.02M | $159.25M | $134.76M | $90.31M | $4.69M | $1.42M | $73.22M | $- | $134.76M |
| Long Term Debt | $438.77M | $445.59M | $452.26M | $234.50M | $221.84M | $403.66M | $410.94M | $404.10M | $413.26M | $59.84M | $51.55M | $27.31M | $22.28M | $16.27M | $16.36M | $16.44M | $16.52M | $- | $22.28M |
| Deferred Revenue Non-Current | $- | $- | $152.87M | $166.07M | $158.06M | $170.01M | $179.90M | $174.81M | $174.77M | $150.64M | $156.98M | $170.18M | $155.99M | $163.04M | $- | $- | $99.65M | $- | $155.99M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $12.26M | $14.15M | $- | $- | $- | $- | $- | $154.58M | $229.90M | $- | $- | $12.68M | $- | $- |
| Other Non-Current Liabilities | $115.36M | $122.92M | $20.89M | $24.88M | $24.43M | $31.57M | $34.24M | $39.01M | $42.06M | $95.66M | $83.61M | $86.95M | $190.58M | $263.00M | $233.90M | $132.28M | $102.68M | $- | $190.58M |
| Total Non-Current Liabilities | $554.12M | $568.51M | $626.03M | $425.45M | $404.33M | $605.25M | $625.08M | $617.92M | $630.08M | $306.14M | $292.14M | $284.43M | $368.85M | $442.31M | $250.26M | $148.72M | $131.88M | $- | $368.85M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $661.39M | $682.94M | $792.18M | $594.49M | $568.19M | $773.71M | $788.41M | $809.62M | $803.04M | $430.96M | $427.16M | $443.68M | $503.61M | $532.62M | $254.95M | $150.14M | $205.10M | $- | $503.61M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $184.00K | $184.00K | $0 | $177.00K | $- |
| Common Stock | $5.00K | $5.00K | $206.00K | $202.00K | $199.00K | $198.00K | $196.00K | $194.00K | $190.00K | $165.00K | $164.00K | $162.00K | $161.00K | $148.00K | $1.47B | $1.57B | $129.00K | $- | $161.00K |
| Retained Earnings | $-5.84B | $-5.73B | $-5.67B | $-5.46B | $-5.29B | $-5.08B | $-4.78B | $-4.60B | $-4.40B | $-4.23B | $-3.56B | $-2.89B | $-2.30B | $-697.27M | $-101.00M | $4.99M | $-467.88M | $- | $-2.30B |
| Accumulated Other Comprehensive Income Loss | $-1.81M | $263.00K | $-1.72M | $-1.55M | $1.48M | $-2.90M | $-1.30M | $-1.61M | $-2.63M | $-7.91M | $-5.50M | $-2.35M | $-1.72M | $-877.00K | $0 | $0 | $-0 | $492.89M | $- |
| Other Total Stockholders Equity | $6.56B | $6.53B | $6.51B | $6.45B | $6.39B | $6.33B | $6.28B | $6.21B | $6.14B | $5.67B | $5.10B | $4.47B | $3.80B | $2.25B | $105.99M | $1.58B | $929.13M | $8.79M | $3.80B |
| Total Stockholders Equity | $716.06M | $797.94M | $833.07M | $987.27M | $1.10B | $1.25B | $1.50B | $1.61B | $1.74B | $1.43B | $1.54B | $1.58B | $1.51B | $1.55B | $1.47B | $1.58B | $461.38M | $501.85M | $1.51B |
| Total Equity | $716.06M | $797.94M | $833.07M | $987.27M | $1.10B | $1.25B | $1.50B | $1.61B | $1.74B | $1.44B | $1.57B | $1.61B | $1.57B | $1.62B | $1.48B | $1.59B | $470.05M | $501.85M | $1.51B |
| Total Liabilities and Stockholders Equity | $1.38B | $1.48B | $1.63B | $1.58B | $1.67B | $2.03B | $2.29B | $2.42B | $2.54B | $1.87B | $1.99B | $2.06B | $2.07B | $2.15B | $1.73B | $1.73B | $675.15M | $501.85M | $2.01B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $5.00M | $31.62M | $33.25M | $62.01M | $66.42M | $6.94M | $7.47M | $8.68M | $- | $- |
| Total Liabilities and Total Equity | $1.38B | $1.48B | $1.63B | $1.58B | $1.67B | $2.03B | $2.29B | $2.42B | $2.54B | $1.87B | $1.99B | $2.06B | $2.07B | $2.15B | $1.73B | $1.73B | $675.15M | $501.85M | $2.01B |
| Total Investments | $48.70M | $62.10M | $120.29M | $133.94M | $132.89M | $84.97M | $119.94M | $122.94M | $113.73M | $95.98M | $95.98M | $111.24M | $115.23M | $121.13M | $1.73B | $1.73B | $103.12M | $990.57M | $- |
| Total Debt | $438.77M | $445.59M | $452.26M | $234.50M | $241.77M | $403.66M | $410.94M | $404.10M | $442.59M | $59.84M | $51.55M | $27.31M | $23.03M | $16.27M | $16.36M | $16.44M | $17.00M | $- | $22.28M |
| Net Debt | $-122.81M | $-170.62M | $-278.10M | $-609.27M | $-707.09M | $-645.58M | $-694.85M | $-801.99M | $-873.20M | $-1.24B | $-1.33B | $-1.47B | $-1.53B | $-1.72B | $16.32M | $14.52M | $-363.80M | $495.29M | $-1.53B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-547.03M | $-892.87M | $-2.11B | $-1.84B | $-126.72M |
| Depreciation and Amortization | $63.02M | $71.55M | $44.42M | $29.08M | $13.86M |
| Deferred Income Tax | $-936.00K | $-801.00K | $-14.61M | $30.21M | $4.13M |
| Stock Based Compensation | $112.34M | $229.88M | $1.93B | $1.61B | $476.00K |
| Change in Working Capital | $- | $29.84M | $-37.01M | $-61.54M | $-26.52M |
| Accounts Receivables | $-4.72M | $50.07M | $55.02M | $-114.09M | $-14.23M |
| Inventory | $- | $- | $164.00K | $-626.00K | $-2.74M |
| Accounts Payables | $4.77M | $-1.18M | $-10.84M | $-2.25M | $7.02M |
| Other Working Capital | $- | $-19.05M | $-81.35M | $55.43M | $-16.57M |
| Other Non Cash Items | $53.02M | $266.89M | $-69.28M | $-20.95M | $-1.06M |
| Net Cash Provided by Operating Activities | $-319.58M | $-295.50M | $-252.20M | $-253.82M | $-135.83M |
| Investments in Property Plant and Equipment | $-62.54M | $-40.80M | $-52.27M | $-56.52M | $-57.82M |
| Acquisitions Net | $-5.40M | $-38.55M | $26.65M | $-12.04M | $- |
| Purchases of Investments | $- | $- | $-3.69M | $-5.00M | $- |
| Sales Maturities of Investments | $4.52M | $- | $- | $- | $- |
| Other Investing Activities | $1.19M | $-1.34M | $-38.08M | $304.00K | $-9.30M |
| Net Cash Used for Investing Activities | $-62.24M | $-80.69M | $-67.39M | $-73.26M | $-67.12M |
| Debt Repayment | $-897.00K | $-1.29M | $-1.24M | $-1.12M | $-748.00K |
| Common Stock Issued | $- | $- | $99.30M | $- | $91.07M |
| Common Stock Repurchased | $- | $-23.00K | $- | $-25.00M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-842.00K | $-1.90M | $-3.96M | $1.56B | $91.07M |
| Net Cash Used Provided by Financing Activities | $-1.74M | $-3.22M | $95.34M | $1.53B | $90.32M |
| Effect of Forex Changes on Cash | $-281.00K | $-588.00K | $908.00K | $-19.00K | $- |
| Net Change in Cash | $-383.84M | $-380.00M | $-223.35M | $1.21B | $-112.63M |
| Cash at End of Period | $605.74M | $989.58M | $1.37B | $1.59B | $385.88M |
| Cash at Beginning of Period | $989.58M | $1.37B | $1.59B | $385.88M | $498.51M |
| Operating Cash Flow | $-319.58M | $-295.50M | $-252.20M | $-253.82M | $-135.83M |
| Capital Expenditure | $-62.54M | $-40.80M | $-52.27M | $-56.52M | $-57.82M |
| Free Cash Flow | $-382.13M | $-336.30M | $-304.47M | $-310.34M | $-193.65M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-107.53M | $-56.40M | $-217.18M | $-165.91M | $-211.69M | $-302.89M | $-173.31M | $-204.97M | $-174.15M | $-669.05M | $-670.57M | $-592.59M | $-1.60B | $-102.41M | $-54.46M | $-74.78M | $-46.40M | $-26.05M | $-28.66M | $-24.97M |
| Depreciation and Amortization | $15.65M | $17.17M | $17.33M | $12.87M | $12.84M | $20.49M | $18.22M | $18.96M | $15.82M | $9.51M | $9.61M | $9.49M | $8.00M | $8.28M | $7.17M | $5.63M | $4.00M | $3.53M | $3.18M | $3.15M |
| Deferred Income Tax | $- | $- | $- | $- | $-801.00K | $146.84M | $67.00K | $- | $-14.61M | $- | $- | $- | $-57.88M | $70.50M | $1.59M | $16.00M | $-3.00M | $6.00K | $- | $- |
| Stock Based Compensation | $20.56M | $13.86M | $37.15M | $40.78M | $42.84M | $52.57M | $61.49M | $72.99M | $108.17M | $563.14M | $606.51M | $652.82M | $1.59B | $127.00K | $14.52M | $118.00K | $118.00K | $118.00K | $117.00K | $123.00K |
| Change in Working Capital | $2.18M | $-6.19M | $5.88M | $312.00K | $51.33M | $-1.82M | $-11.88M | $1.49M | $-18.75M | $44.86M | $-52.97M | $-10.15M | $-92.34M | $25.25M | $2.49M | $3.07M | $-13.30M | $-5.44M | $2.16M | $421.00K |
| Accounts Receivables | $1.38M | $-5.00M | $5.67M | $-6.77M | $28.90M | $5.77M | $15.92M | $-526.00K | $34.50M | $59.12M | $-3.67M | $-34.93M | $-85.42M | $-22.19M | $3.06M | $-9.54M | $-7.44M | $-10.12M | $3.85M | $-508.00K |
| Inventory | $- | $- | $- | $- | $-10.78M | $8.23M | $694.00K | $1.85M | $2.66M | $2.24M | $595.00K | $-5.33M | $112.00K | $-758.00K | $701.00K | $-681.00K | $-1.92M | $-819.00K | $- | $- |
| Accounts Payables | $35.87M | $-41.96M | $-7.00K | $10.87M | $3.64M | $-7.82M | $-6.69M | $9.68M | $-14.74M | $-6.76M | $-15.60M | $26.25M | $524.00K | $4.55M | $-7.84M | $516.00K | $4.32M | $- | $- | $- |
| Other Working Capital | $-35.07M | $40.77M | $219.00K | $-3.79M | $29.57M | $-8.01M | $-21.81M | $-9.52M | $-41.18M | $-9.74M | $-34.30M | $3.86M | $-7.55M | $43.64M | $6.56M | $12.78M | $-8.25M | $5.50M | $-1.68M | $929.00K |
| Other Non Cash Items | $26.71M | $-71.93M | $72.44M | $85.11M | $56.93M | $11.27M | $31.89M | $20.95M | $-21.18M | $23.25M | $8.12M | $-79.47M | $-9.58M | $-6.98M | $-6.21M | $1.82M | $-766.00K | $2.58M | $-4.01M | $-2.74M |
| Net Cash Provided by Operating Activities | $-42.44M | $-103.50M | $-84.39M | $-89.26M | $-48.55M | $-73.55M | $-73.53M | $-90.58M | $-104.70M | $-28.30M | $-99.30M | $-19.90M | $-165.54M | $-5.24M | $-34.91M | $-48.13M | $-59.34M | $-25.27M | $-27.21M | $-24.01M |
| Investments in Property Plant and Equipment | $-13.71M | $-15.09M | $-27.03M | $-6.71M | $-3.45M | $-4.38M | $-13.53M | $-19.44M | $-25.64M | $-13.47M | $-9.57M | $-3.58M | $-5.11M | $-5.44M | $-24.03M | $-21.93M | $-19.41M | $-28.67M | $-6.46M | $-3.28M |
| Acquisitions Net | $- | $-191.00K | $- | $-5.40M | $-41.55M | $74.00K | $2.31M | $617.00K | $83.02M | $-29.05M | $1.44M | $-28.77M | $9.34M | $-20.17M | $- | $-1.21M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $10.00M | $-10.00M | $-6.50M | $-3.69M | $-5.00M | $-5.00M | $- | $-1.73B | $- | $- | $- | $- |
| Sales Maturities of Investments | $568.00K | $3.95M | $- | $- | $- | $- | $- | $- | $- | $- | $6.50M | $- | $4.70M | $-124.30K | $124.30K | $- | $- | $- | $- | $- |
| Other Investing Activities | $57.00K | $1.13M | $191.00K | $- | $-1.68M | $926.00K | $2.31M | $-590.00K | $-37.64M | $6.03M | $-6.53M | $58.00K | $304.00K | $102.00K | $103.00K | $99.00K | $-9.42M | $106.00K | $11.00K | $- |
| Net Cash Used for Investing Activities | $-13.09M | $-10.20M | $-26.84M | $-12.11M | $-46.67M | $-3.38M | $-11.22M | $-19.41M | $29.74M | $-46.49M | $-14.66M | $-35.98M | $4.23M | $-30.51M | $-23.93M | $-23.05M | $-28.83M | $-28.56M | $-6.45M | $-3.28M |
| Debt Repayment | $-203.00K | $-200.00K | $-200.00K | $-294.00K | $-318.00K | $-329.00K | $-326.00K | $-322.00K | $-155.00K | $-303.00K | $-434.00K | $-286.00K | $-359.00K | $-316.00K | $-163.00K | $-285.00K | $-193.00K | $-160.00K | $-190.00K | $-205.00K |
| Common Stock Issued | $- | $-84.00K | $14.00K | $70.00K | $-487.00K | $- | $566.00K | $-566.00K | $98.09M | $-88.00K | $- | $75.00K | $167.00K | $-242.77M | $- | $1.75B | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $-23.00K | $- | $-12.00K | $- | $- | $- | $-75.00K | $-981.00K | $-9.46M | $-25.00M | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-554.00K | $- | $- | $- | $- | $- | $- | $- | $-24.96M | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-265.00K | $-26.00K | $-551.00K | $727.00K | $14.00K | $-1.05M | $-566.00K | $-1.22M | $-88.00K | $-334.00K | $-906.00K | $-1.22M | $1.55B | $-1.96M | $-148.00K | $7.00K | $22.43M | $72.01M | $-3.38M |
| Net Cash Used Provided by Financing Activities | $-203.00K | $-465.00K | $-226.00K | $-845.00K | $-632.00K | $-315.00K | $-1.38M | $-888.00K | $97.93M | $-450.00K | $-954.00K | $-1.19M | $-11.04M | $1.55B | $-2.12M | $-433.00K | $-186.00K | $22.27M | $71.82M | $-3.58M |
| Effect of Forex Changes on Cash | $-73.00K | $-35.00K | $-16.00K | $-157.00K | $102.00K | $-195.00K | $-469.00K | $-26.00K | $1.10M | $-87.00K | $-96.00K | $-8.00K | $-11.00K | $-8.00K | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-55.80M | $-114.20M | $-111.47M | $-105.09M | $-103.73M | $-77.44M | $-86.61M | $-110.91M | $24.07M | $-75.33M | $-115.01M | $-57.08M | $-172.37M | $1.51B | $-60.97M | $-71.61M | $-88.36M | $-31.56M | $38.16M | $-30.88M |
| Cash at End of Period | $605.74M | $661.54M | $732.72M | $843.77M | $948.86M | $1.09B | $1.17B | $1.26B | $1.37B | $1.35B | $1.42B | $1.54B | $1.59B | $1.77B | $253.30M | $314.27M | $385.88M | $474.23M | $505.80M | $467.63M |
| Cash at Beginning of Period | $661.54M | $775.74M | $843.77M | $948.86M | $1.05B | $1.17B | $1.26B | $1.37B | $1.35B | $1.42B | $1.54B | $1.59B | $1.77B | $253.30M | $314.27M | $385.88M | $474.23M | $505.80M | $467.63M | $498.51M |
| Operating Cash Flow | $-42.44M | $-103.50M | $-84.39M | $-89.26M | $-48.55M | $-73.55M | $-73.53M | $-90.58M | $-104.70M | $-28.30M | $-99.30M | $-19.90M | $-165.54M | $-5.24M | $-34.91M | $-48.13M | $-59.34M | $-25.27M | $-27.21M | $-24.01M |
| Capital Expenditure | $-13.71M | $-15.09M | $-27.03M | $-6.71M | $-3.45M | $-4.38M | $-13.53M | $-19.44M | $-25.64M | $-13.47M | $-9.57M | $-3.58M | $-5.11M | $-5.44M | $-24.03M | $-21.93M | $-19.41M | $-28.67M | $-6.46M | $-3.28M |
| Free Cash Flow | $-56.15M | $-118.59M | $-111.42M | $-95.97M | $-52.00M | $-77.93M | $-87.07M | $-110.03M | $-130.35M | $-41.77M | $-108.87M | $-23.48M | $-170.66M | $-10.67M | $-58.95M | $-70.07M | $-78.75M | $-53.94M | $-33.67M | $-27.29M |
Ginkgo Bioworks Holdings Dividends
Explore Ginkgo Bioworks Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Ginkgo Bioworks Holdings News
Read the latest news about Ginkgo Bioworks Holdings, including recent articles, headlines, and updates.
Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market
Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed comprehensive overview of the circulating DNA/RNA patent landscape discloses remarkable industry growth projections, with an expected surge from USD 5.32 billion in 2023 to USD 16.4 billion by 2032. The market is advancing at an impressive compound annual growth rate (CAGR) of 13.29%, driven by innovations in nucleic acid-based therapeutics and diagnostics. Patent Landscape Overview The report provides a thorough examination of blood-based biomarkers critical for non-invasive diagnostics in various conditions ranging from cancer to genetic disorders. The increasing number of patents in next-generation sequencing, cancer biomarkers, and therapeutic delivery systems are significantly shaping the industry landscape, propelling advancements in non-invasive diagnostics and personalised medicine. Regional Patent Activity Highlights Insights into the patent activity emphasize the dominance of the United States with over 600 patents, closely pursued by Europe and Asia, with 400 and 250 patents respectively. These regions underscore significant contributions to the industry, each with distinctive advantages in the biotech sector and supportive government initiatives that enhance the competitive position on a global scale. Segmentation Analysis The patent landscape encompasses a myriad of segments, primarily led by the oncology sector with a notable number of filings. Innovations in non-invasive diagnostics and personalised medicine are elucidated, showcasing strategic focus areas for major actors in the field. Furthermore, the in-depth analysis spells out the dynamics within technologies and indications, predicting continued growth and expansion into diverse medical applications. Key Industry Players Prominent market participants such as Nantomics, Genentech Inc., and Novartis AG are pivotal in the development of the circulating DNA/RNA patent landscape. These companies hold substantive patents in detection, analysis, and therapeutic applications of circulating nucleic acids, reinforcing their impact on the overall industry growth and innovation trajectory. Strategic Insights and Future Opportunities The comprehensive analysis of the patent landscape signifies a vibrant and advancing sector, providing strategic insights into industry dynamics and future opportunities. As patents continue to drive the expansion of this domain, stakeholders and industry participants can anticipate new technological frontiers in personalised medicine and non-invasive diagnostic methodologies, ultimately enhancing patient care and healthcare outcomes. This landmark report reflects the propulsive nature of the circulating DNA/RNA sector, offering critical insights that underpin the unfolding narrative of genomic medicine and its expansive potential. Key Attributes:
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19.
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and n.
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab
BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto.
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office (JPO) in January 2025.
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation
Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
DNA from Fiserv Selected by Third Federal as Part of its Digital Transformation
MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced it will deliver digital innovation through the award-winning DNA® platform to Third Federal Savings & Loan. The platform will better equip Third Federal to serve account holders through future-ready technologies and real-time transactions via all channels, propelling customization and growth. Third Federal, a $17bn bank based in Cleveland, selected DN.
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company's Form 10-Q, once filed, can be viewed on the SEC Filings page of its Investor Relations website.
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m.
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@kingsdaleadvisors.com.
Mercado Libre CEO and Founder Marcos Galperin Reflects on the company's 25-Year Journey and DNA in Latest Episode of Inside Mercado Libre
Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podcast series, Inside Mercado Libre, "Marcos Galperin on MELI's Culture” featuring its CEO and founder Marcos Galperin. The Inside Mercado Libre podcast, hosted by Investor Relations Officer, Richard Cathcart, provides investors with unique access to the company executives' strategic views.
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series
Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DNA.